The Enterprise Value as of December 2025 (TTM) for Inhibikase Therapeutics, Inc. (IKT) is 75.20M

According to Inhibikase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 75.20M. This represents a change of -39.50% compared to the average of 124.30M of the last 4 quarters.

Inhibikase Therapeutics, Inc. (IKT) Historical Enterprise Value (quarterly & annually)

How has IKT Enterprise Value performed in the past?

The mean historical Enterprise Value of Inhibikase Therapeutics, Inc. over the last ten years is 64.10M. The current 75.20M Enterprise Value has changed 11.63% with respect to the historical average. Over the past ten years (40 quarters), IKT's Enterprise Value was at its highest in in the December 2024 quarter at 169.05M. The Enterprise Value was at its lowest in in the June 2022 quarter at -13460170.32.

Inhibikase Therapeutics, Inc. (IKT) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Inhibikase Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Inhibikase Therapeutics, Inc. (IKT) Average Enterprise Value

How has IKT Enterprise Value performed in the past?

The current Enterprise Value of Inhibikase Therapeutics, Inc. (IKT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Inhibikase Therapeutics, Inc. (IKT) Enterprise Value vs. Peers

How is IKT’s Enterprise Value compared to its peers?

Inhibikase Therapeutics, Inc.’s Enterprise Value is less than Turn Therapeutics Inc. (122.05M), less than Cognition Therapeutics, Inc. (119.19M), greater than Surrozen, Inc. (73.38M), less than Tevogen Bio Holdings Inc. (85.88M), less than Greenwich LifeSciences, Inc. (118.02M), less than eXoZymes, Inc. (121.71M), greater than Estrella Immunopharma, Inc. (71.57M), greater than Atossa Therapeutics, Inc. (40.25M), less than Agenus Inc. (181.50M), less than Entera Bio Ltd. (88.38M),

Build a custom stock screener for Inhibikase Therapeutics, Inc. (IKT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibikase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibikase Therapeutics, Inc. (IKT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibikase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.